title: Why is coronary collateral growth impaired in type II diabetes and the metabolic syndrome?
abstract: Type II diabetes and the metabolic syndrome are strong predictors of severity of occlusive coronary disease and poorer outcomes of coronary revascularization therapies. Coronary collateral growth can provide an alternative or accessory pathway of revascularization. However, collateral growth is impaired in type II diabetes and the metabolic syndrome. Although many factors necessary for collateral growth are known and many interventions have shown promising results in animal studies, not a single attempt to induce coronary collateral growth in human clinical trials has led to satisfactory results. Accordingly, the first part of this review outlines the known deleterious effects of diabetes and the metabolic syndrome on factors necessary for collateral growth, including pro-angiogenic growth factors, endothelial function, the redox state of the coronary circulation, intracellular signaling, leukocytes and bone marrow-derived progenitors cells. The second section highlights the gaps in our current knowledge of how these factors interact with the radically altered environment of the coronary circulation in diabetes and the metabolic syndrome. The interplay between these pathologies and inadequately explored areas related to the temporal regulation of collateral remodeling and the roles of the extracellular matrix, vascular cell phenotype and pro-inflammatory cytokines are emphasized with implications to development of efficient therapies.
authors.affiliation: Department of Biochemistry and Molecular Biology, University of South Alabama College of Medicine, Mobile, AL 36688, United States. procic@usouthal.edu
authors.forename: Petra
authors.initials: P
authors.lastname: Rocic
mesh_terms: D000818:Animals; D003097:Collateral Circulation; D003326:Coronary Circulation; D054059:Coronary Occlusion / Q000503:physiopathology* / Q000628:therapy; D016207:Cytokines / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000503:physiopathology*; D005109:Extracellular Matrix / Q000378:metabolism; D006801:Humans; D024821:Metabolic Syndrome / Q000503:physiopathology*; D012720:Severity of Illness Index
chemical_list: D016207:Cytokines